Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cadonilimab + paclitaxel + carboplatin is a combination therapy that pairs a novel bispecific antibody with standard chemotherapy. Cadonilimab is a tetravalent bispecific antibody targeting both PD-1 and CTLA-4 immune checkpoints with an Fc-null design that eliminates antibody-dependent cellular cytotoxicity and phagocytosis, enhancing safety. Paclitaxel is a taxane chemotherapy that stabilizes microtubules and prevents cell division. Carboplatin is a platinum-based chemotherapy that forms DNA crosslinks. This combination has shown promising efficacy in clinical trials for cervical cancer, with significantly prolonged progression-free survival compared to chemotherapy alone.
- Brand names
- Kaitanni
- Other names
- cadonilimab + carboplatin + paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cadonilimab + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + paclitaxel + carboplatin.